Which telehealth categories still have margin in 2026
The short answer
Not generic weight loss and not commodity men's health. Both are crowded, both are discounting, and the drug makers now sell direct in the first one. The room is in categories that need ongoing clinical attention rather than a monthly vial: testosterone, hormone therapy and menopause, metabolic health, and longevity. The pattern underneath is more useful than the list. Margin survives where a patient is buying a programme they stay in, and disappears where they are buying a product they can price-compare.
Why did weight loss get hard?
Three things happened at once. The shortages ended, so the compounded price advantage went with them. The manufacturers started selling direct, which reset what a patient expects to pay. And several thousand brands had already entered on the assumption that a cheap vial was a business.
What is left is a category where the product is identical everywhere and the only lever is price, which is the definition of a commodity. Brands still doing well in it are not winning on the medication. They are winning on labs, side-effect management, dose titration and a reason to still be there in month six.
It is not closed. It is just no longer a category you can enter with a storefront and a supplier.
Where is the room?
Testosterone. Ongoing by nature, needs monitoring, and the clinical relationship is the product. The constraint is real and worth knowing before you build: it is a controlled medication, so there is no refill shortcut and every renewal is a fresh visit with a fresh fee. That is covered properly in the TRT article.
Hormone therapy and menopause. Badly served for decades, actively searched, and a patient population that stays for years rather than months. It rewards clinical depth rather than acquisition spend.
Metabolic health beyond the GLP-1. Labs, continuous monitoring, and the medication as one part. Harder to build and much harder to copy.
Longevity. Sermorelin, NAD+ and the six peptides that opened for compounding in October 2026. Early, genuinely in demand, and the regulatory ground moves, which is covered on the peptides pages.
Women's health more broadly. The clearest gap between what patients want and what exists.
What makes a category defensible?
Three questions sort it faster than a market report.
Does the patient need a clinician more than once? If the entire clinical event is the first prescription, you are selling a product and will compete on price forever.
Can a competitor copy your offer in a week? A molecule and a price can. A lab panel, a titration protocol and a nurse who answers messages cannot.
Does the category tolerate being advertised? Some cannot be advertised at all on the major platforms, which means organic and referral, which means slower and more durable. Knowing that going in changes what you build first.
What does this mean for a first launch?
Pick one category and go deep rather than listing twelve. Every additional product is another intake to maintain, another set of state rules and another thing to keep priced, and brands that launch wide usually sell two of their twelve.
The cheapest honest test is one category, three states and ten real orders run end to end. That tells you whether anyone buys, which is the only thing worth knowing in month one.
Our cost breakdown has the arithmetic, and the states article covers which three.
Questions
Is weight loss a dead category?
No, but it is no longer an easy one. The brands doing well pair the medication with labs, coaching and side-effect management rather than competing on the price of a vial.
What is the single most underserved category?
Menopause and hormone therapy, by most measures. Decades of under-treatment, high search volume, and patients who stay for years.
Should I start with peptides?
Only alongside something established. Six peptides opened for compounding in October 2026 under an interim policy that can be withdrawn, so a store built only on them is a store with one regulatory decision between it and nothing.
How many products should I launch with?
Two or three. Every product is an intake, a set of state rules and a price to maintain, and a wide catalogue on day one almost always means a thin one.
Does picking a crowded category mean I cannot compete?
It means you cannot compete on the medication. Retention, clinical depth and service are still wide open in every category named here.